HomepageMedicineFDA Approves Revuforj to Treat R/R Acute Leukemia with KMT2A Translocation Medicine FDA Approves Revuforj to Treat R/R Acute Leukemia with KMT2A Translocation admin Posted on November 20, 2024 Syndax describes the drug as the first of its kind. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostKolkata: Godrej Properties buys 53-acre land parcel in Joka Next PostHow Two High-Profile New York Industries Might Fare Under Trump You Might Also Like Medicine FDA Grants Fast Track Designation to Adicet Bio’s CAR T-cell Therapy for Systemic Lupus Erythematosus admin February 5, 2025 Medicine Samgsung Biologics, LegoChem Biosciences Partner on Development of Antibody-Drug Conjugate admin February 11, 2024 Medicine Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes admin September 6, 2024 Medicine CMS Signals Looming Sunshine Act Audits: How to Prepare admin March 2, 2024
Medicine FDA Grants Fast Track Designation to Adicet Bio’s CAR T-cell Therapy for Systemic Lupus Erythematosus admin February 5, 2025
Medicine Samgsung Biologics, LegoChem Biosciences Partner on Development of Antibody-Drug Conjugate admin February 11, 2024
Medicine Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes admin September 6, 2024